Gram-Positive Bacterial Infection

The FDA approved the AbbVie’s Dalvance (dalbavancin) for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth, according to a press release.

Reducing fluoroquinolone and piperacillin-tazobactam use may decrease resistance in nonfermenting bacteria, according to a recent study published in Open Forum Infectious Diseases.